Thromboembolic events and thromboprophylaxis associated with immunomodulators in multiple myeloma patients: a real-life study
Purpose The aim of this study is to assess international guidelines implementation concerning thromboprophylaxis strategy in myeloma patients treated with immunomodulatory drugs. Methods This retrospective study includes multiple myeloma patients treated with immunomodulatory drugs between 2014 and...
Gespeichert in:
| Veröffentlicht in: | Journal of cancer research and clinical oncology 2022-04, Vol.148 (4), p.975-984 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 984 |
|---|---|
| container_issue | 4 |
| container_start_page | 975 |
| container_title | Journal of cancer research and clinical oncology |
| container_volume | 148 |
| creator | Leclerc, V. Karlin, L. Herledan, C. Marchal, L. Baudouin, A. Gouraud, A. Caffin, A. G. Larbre, V. Lazareth, A. Bachy, E. Salles, G. Ghesquières, H. Rioufol, C. Ranchon, F. |
| description | Purpose
The aim of this study is to assess international guidelines implementation concerning thromboprophylaxis strategy in myeloma patients treated with immunomodulatory drugs.
Methods
This retrospective study includes multiple myeloma patients treated with immunomodulatory drugs between 2014 and 2017 in the Hematology department of a teaching hospital (Hospices Civils de Lyon, France) and followed by the multidisciplinary care plan for cancer outpatients ONCORAL (ONCological care for outpatients with ORAL anticancer drugs). Data from immunomodulatory drugs administration, thromboprophylaxis strategy and thrombotic events were collected from medical files. Adherence to 2010 International Myeloma Working Group (IMWG) guidelines was assessed.
Results
213 patients received at least one immunomodulatory drug: lenalidomide (60.9%), pomalidomide (24.0%) and thalidomide (15.1%). About two third of treatment lines (66.2%) were in accordance with IMWG recommendations. Among the others, 30.5% and 69.5% had thromboprophylaxis, respectively, superior or inferior to IMWG recommendations. 37 venous thrombotic events and 4 arterial thromboembolisms (one patient experienced both a stroke and deep venous thrombosis simultaneously) were reported.
Conclusion
Thromboprophylaxis was systematically performed in myeloma patients treated with immunomodulatory drugs in this real-life retrospective cohort. However, the choice of anticoagulant or anti-platelet agent remains debatable, as adherence to existing guidelines was variable. |
| doi_str_mv | 10.1007/s00432-021-03693-5 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_hal_p</sourceid><recordid>TN_cdi_proquest_miscellaneous_2543444297</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2640563778</sourcerecordid><originalsourceid>FETCH-LOGICAL-c409t-82d1b72f1f3ff818d57d90b7a3a424f8c28aa47b046e81017f943470bf106ea63</originalsourceid><addsrcrecordid>eNp9kc1u1TAQhS0EopfCC7BAltjAIuC_xAm7qgKKdKVuytqaJDbXlR0H2yncBe-O05QiddGFZXnmmzM-Ogi9puQDJUR-TIQIzirCaEV40_GqfoJ2dC1RzuunaEeopFXNaHOCXqR0Tcq7luw5OuFixXi3Q3-uDjH4PuhynB2wvtFTThimEeetM8cwH44OfttSTikMFrIe8S-bD9h6v0zBh3FxkENM2E7YLy7b2Wnsj9oFD3iGbFfRTxhw1OAqZ43GKS_j8SV6ZsAl_eruPkXfv3y-Or-o9pdfv52f7atBkC5XLRtpL5mhhhvT0nas5diRXgIHwYRpB9YCCNkT0eiWFpemE1xI0htKGg0NP0XvN90DODVH6yEeVQCrLs72aq0R0bGONe0NLey7jS3Gfy46ZeVtGrRzMOmwJMXqoi0E62RB3z5Ar8MSp-JEsUaQuuFStoViGzXEkFLU5v4HlKg1SLUFqUqQ6jZIVZehN3fSS-_1eD_yL7kC8A1IpTX90PH_7kdk_wJ0Uanz</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2640563778</pqid></control><display><type>article</type><title>Thromboembolic events and thromboprophylaxis associated with immunomodulators in multiple myeloma patients: a real-life study</title><source>SpringerLink Journals</source><creator>Leclerc, V. ; Karlin, L. ; Herledan, C. ; Marchal, L. ; Baudouin, A. ; Gouraud, A. ; Caffin, A. G. ; Larbre, V. ; Lazareth, A. ; Bachy, E. ; Salles, G. ; Ghesquières, H. ; Rioufol, C. ; Ranchon, F.</creator><creatorcontrib>Leclerc, V. ; Karlin, L. ; Herledan, C. ; Marchal, L. ; Baudouin, A. ; Gouraud, A. ; Caffin, A. G. ; Larbre, V. ; Lazareth, A. ; Bachy, E. ; Salles, G. ; Ghesquières, H. ; Rioufol, C. ; Ranchon, F.</creatorcontrib><description>Purpose
The aim of this study is to assess international guidelines implementation concerning thromboprophylaxis strategy in myeloma patients treated with immunomodulatory drugs.
Methods
This retrospective study includes multiple myeloma patients treated with immunomodulatory drugs between 2014 and 2017 in the Hematology department of a teaching hospital (Hospices Civils de Lyon, France) and followed by the multidisciplinary care plan for cancer outpatients ONCORAL (ONCological care for outpatients with ORAL anticancer drugs). Data from immunomodulatory drugs administration, thromboprophylaxis strategy and thrombotic events were collected from medical files. Adherence to 2010 International Myeloma Working Group (IMWG) guidelines was assessed.
Results
213 patients received at least one immunomodulatory drug: lenalidomide (60.9%), pomalidomide (24.0%) and thalidomide (15.1%). About two third of treatment lines (66.2%) were in accordance with IMWG recommendations. Among the others, 30.5% and 69.5% had thromboprophylaxis, respectively, superior or inferior to IMWG recommendations. 37 venous thrombotic events and 4 arterial thromboembolisms (one patient experienced both a stroke and deep venous thrombosis simultaneously) were reported.
Conclusion
Thromboprophylaxis was systematically performed in myeloma patients treated with immunomodulatory drugs in this real-life retrospective cohort. However, the choice of anticoagulant or anti-platelet agent remains debatable, as adherence to existing guidelines was variable.</description><identifier>ISSN: 0171-5216</identifier><identifier>EISSN: 1432-1335</identifier><identifier>DOI: 10.1007/s00432-021-03693-5</identifier><identifier>PMID: 34143239</identifier><language>eng</language><publisher>Berlin/Heidelberg: Springer Berlin Heidelberg</publisher><subject>Antineoplastic drugs ; Antiplatelet therapy ; Antitumor agents ; Cancer Research ; Drugs ; Hematology ; Immunomodulation ; Immunomodulators ; Internal Medicine ; Life Sciences ; Medicine ; Medicine & Public Health ; Multiple myeloma ; Oncology ; Original Article – Clinical Oncology ; Patients ; Thalidomide ; Thromboembolism ; Thrombosis</subject><ispartof>Journal of cancer research and clinical oncology, 2022-04, Vol.148 (4), p.975-984</ispartof><rights>The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature 2021</rights><rights>2021. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.</rights><rights>The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature 2021.</rights><rights>Distributed under a Creative Commons Attribution 4.0 International License</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c409t-82d1b72f1f3ff818d57d90b7a3a424f8c28aa47b046e81017f943470bf106ea63</citedby><cites>FETCH-LOGICAL-c409t-82d1b72f1f3ff818d57d90b7a3a424f8c28aa47b046e81017f943470bf106ea63</cites><orcidid>0000-0002-9181-4231</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s00432-021-03693-5$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s00432-021-03693-5$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>230,314,776,780,881,27901,27902,41464,42533,51294</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/34143239$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink><backlink>$$Uhttps://hal.science/hal-04929268$$DView record in HAL$$Hfree_for_read</backlink></links><search><creatorcontrib>Leclerc, V.</creatorcontrib><creatorcontrib>Karlin, L.</creatorcontrib><creatorcontrib>Herledan, C.</creatorcontrib><creatorcontrib>Marchal, L.</creatorcontrib><creatorcontrib>Baudouin, A.</creatorcontrib><creatorcontrib>Gouraud, A.</creatorcontrib><creatorcontrib>Caffin, A. G.</creatorcontrib><creatorcontrib>Larbre, V.</creatorcontrib><creatorcontrib>Lazareth, A.</creatorcontrib><creatorcontrib>Bachy, E.</creatorcontrib><creatorcontrib>Salles, G.</creatorcontrib><creatorcontrib>Ghesquières, H.</creatorcontrib><creatorcontrib>Rioufol, C.</creatorcontrib><creatorcontrib>Ranchon, F.</creatorcontrib><title>Thromboembolic events and thromboprophylaxis associated with immunomodulators in multiple myeloma patients: a real-life study</title><title>Journal of cancer research and clinical oncology</title><addtitle>J Cancer Res Clin Oncol</addtitle><addtitle>J Cancer Res Clin Oncol</addtitle><description>Purpose
The aim of this study is to assess international guidelines implementation concerning thromboprophylaxis strategy in myeloma patients treated with immunomodulatory drugs.
Methods
This retrospective study includes multiple myeloma patients treated with immunomodulatory drugs between 2014 and 2017 in the Hematology department of a teaching hospital (Hospices Civils de Lyon, France) and followed by the multidisciplinary care plan for cancer outpatients ONCORAL (ONCological care for outpatients with ORAL anticancer drugs). Data from immunomodulatory drugs administration, thromboprophylaxis strategy and thrombotic events were collected from medical files. Adherence to 2010 International Myeloma Working Group (IMWG) guidelines was assessed.
Results
213 patients received at least one immunomodulatory drug: lenalidomide (60.9%), pomalidomide (24.0%) and thalidomide (15.1%). About two third of treatment lines (66.2%) were in accordance with IMWG recommendations. Among the others, 30.5% and 69.5% had thromboprophylaxis, respectively, superior or inferior to IMWG recommendations. 37 venous thrombotic events and 4 arterial thromboembolisms (one patient experienced both a stroke and deep venous thrombosis simultaneously) were reported.
Conclusion
Thromboprophylaxis was systematically performed in myeloma patients treated with immunomodulatory drugs in this real-life retrospective cohort. However, the choice of anticoagulant or anti-platelet agent remains debatable, as adherence to existing guidelines was variable.</description><subject>Antineoplastic drugs</subject><subject>Antiplatelet therapy</subject><subject>Antitumor agents</subject><subject>Cancer Research</subject><subject>Drugs</subject><subject>Hematology</subject><subject>Immunomodulation</subject><subject>Immunomodulators</subject><subject>Internal Medicine</subject><subject>Life Sciences</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Multiple myeloma</subject><subject>Oncology</subject><subject>Original Article – Clinical Oncology</subject><subject>Patients</subject><subject>Thalidomide</subject><subject>Thromboembolism</subject><subject>Thrombosis</subject><issn>0171-5216</issn><issn>1432-1335</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><sourceid>8G5</sourceid><sourceid>BENPR</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNp9kc1u1TAQhS0EopfCC7BAltjAIuC_xAm7qgKKdKVuytqaJDbXlR0H2yncBe-O05QiddGFZXnmmzM-Ogi9puQDJUR-TIQIzirCaEV40_GqfoJ2dC1RzuunaEeopFXNaHOCXqR0Tcq7luw5OuFixXi3Q3-uDjH4PuhynB2wvtFTThimEeetM8cwH44OfttSTikMFrIe8S-bD9h6v0zBh3FxkENM2E7YLy7b2Wnsj9oFD3iGbFfRTxhw1OAqZ43GKS_j8SV6ZsAl_eruPkXfv3y-Or-o9pdfv52f7atBkC5XLRtpL5mhhhvT0nas5diRXgIHwYRpB9YCCNkT0eiWFpemE1xI0htKGg0NP0XvN90DODVH6yEeVQCrLs72aq0R0bGONe0NLey7jS3Gfy46ZeVtGrRzMOmwJMXqoi0E62RB3z5Ar8MSp-JEsUaQuuFStoViGzXEkFLU5v4HlKg1SLUFqUqQ6jZIVZehN3fSS-_1eD_yL7kC8A1IpTX90PH_7kdk_wJ0Uanz</recordid><startdate>20220401</startdate><enddate>20220401</enddate><creator>Leclerc, V.</creator><creator>Karlin, L.</creator><creator>Herledan, C.</creator><creator>Marchal, L.</creator><creator>Baudouin, A.</creator><creator>Gouraud, A.</creator><creator>Caffin, A. G.</creator><creator>Larbre, V.</creator><creator>Lazareth, A.</creator><creator>Bachy, E.</creator><creator>Salles, G.</creator><creator>Ghesquières, H.</creator><creator>Rioufol, C.</creator><creator>Ranchon, F.</creator><general>Springer Berlin Heidelberg</general><general>Springer Nature B.V</general><general>Springer Verlag</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7TO</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>H94</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>M2O</scope><scope>MBDVC</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope><scope>7X8</scope><scope>1XC</scope><orcidid>https://orcid.org/0000-0002-9181-4231</orcidid></search><sort><creationdate>20220401</creationdate><title>Thromboembolic events and thromboprophylaxis associated with immunomodulators in multiple myeloma patients: a real-life study</title><author>Leclerc, V. ; Karlin, L. ; Herledan, C. ; Marchal, L. ; Baudouin, A. ; Gouraud, A. ; Caffin, A. G. ; Larbre, V. ; Lazareth, A. ; Bachy, E. ; Salles, G. ; Ghesquières, H. ; Rioufol, C. ; Ranchon, F.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c409t-82d1b72f1f3ff818d57d90b7a3a424f8c28aa47b046e81017f943470bf106ea63</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>Antineoplastic drugs</topic><topic>Antiplatelet therapy</topic><topic>Antitumor agents</topic><topic>Cancer Research</topic><topic>Drugs</topic><topic>Hematology</topic><topic>Immunomodulation</topic><topic>Immunomodulators</topic><topic>Internal Medicine</topic><topic>Life Sciences</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Multiple myeloma</topic><topic>Oncology</topic><topic>Original Article – Clinical Oncology</topic><topic>Patients</topic><topic>Thalidomide</topic><topic>Thromboembolism</topic><topic>Thrombosis</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Leclerc, V.</creatorcontrib><creatorcontrib>Karlin, L.</creatorcontrib><creatorcontrib>Herledan, C.</creatorcontrib><creatorcontrib>Marchal, L.</creatorcontrib><creatorcontrib>Baudouin, A.</creatorcontrib><creatorcontrib>Gouraud, A.</creatorcontrib><creatorcontrib>Caffin, A. G.</creatorcontrib><creatorcontrib>Larbre, V.</creatorcontrib><creatorcontrib>Lazareth, A.</creatorcontrib><creatorcontrib>Bachy, E.</creatorcontrib><creatorcontrib>Salles, G.</creatorcontrib><creatorcontrib>Ghesquières, H.</creatorcontrib><creatorcontrib>Rioufol, C.</creatorcontrib><creatorcontrib>Ranchon, F.</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Research Library</collection><collection>Research Library (Corporate)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><collection>Hyper Article en Ligne (HAL)</collection><jtitle>Journal of cancer research and clinical oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Leclerc, V.</au><au>Karlin, L.</au><au>Herledan, C.</au><au>Marchal, L.</au><au>Baudouin, A.</au><au>Gouraud, A.</au><au>Caffin, A. G.</au><au>Larbre, V.</au><au>Lazareth, A.</au><au>Bachy, E.</au><au>Salles, G.</au><au>Ghesquières, H.</au><au>Rioufol, C.</au><au>Ranchon, F.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Thromboembolic events and thromboprophylaxis associated with immunomodulators in multiple myeloma patients: a real-life study</atitle><jtitle>Journal of cancer research and clinical oncology</jtitle><stitle>J Cancer Res Clin Oncol</stitle><addtitle>J Cancer Res Clin Oncol</addtitle><date>2022-04-01</date><risdate>2022</risdate><volume>148</volume><issue>4</issue><spage>975</spage><epage>984</epage><pages>975-984</pages><issn>0171-5216</issn><eissn>1432-1335</eissn><abstract>Purpose
The aim of this study is to assess international guidelines implementation concerning thromboprophylaxis strategy in myeloma patients treated with immunomodulatory drugs.
Methods
This retrospective study includes multiple myeloma patients treated with immunomodulatory drugs between 2014 and 2017 in the Hematology department of a teaching hospital (Hospices Civils de Lyon, France) and followed by the multidisciplinary care plan for cancer outpatients ONCORAL (ONCological care for outpatients with ORAL anticancer drugs). Data from immunomodulatory drugs administration, thromboprophylaxis strategy and thrombotic events were collected from medical files. Adherence to 2010 International Myeloma Working Group (IMWG) guidelines was assessed.
Results
213 patients received at least one immunomodulatory drug: lenalidomide (60.9%), pomalidomide (24.0%) and thalidomide (15.1%). About two third of treatment lines (66.2%) were in accordance with IMWG recommendations. Among the others, 30.5% and 69.5% had thromboprophylaxis, respectively, superior or inferior to IMWG recommendations. 37 venous thrombotic events and 4 arterial thromboembolisms (one patient experienced both a stroke and deep venous thrombosis simultaneously) were reported.
Conclusion
Thromboprophylaxis was systematically performed in myeloma patients treated with immunomodulatory drugs in this real-life retrospective cohort. However, the choice of anticoagulant or anti-platelet agent remains debatable, as adherence to existing guidelines was variable.</abstract><cop>Berlin/Heidelberg</cop><pub>Springer Berlin Heidelberg</pub><pmid>34143239</pmid><doi>10.1007/s00432-021-03693-5</doi><tpages>10</tpages><orcidid>https://orcid.org/0000-0002-9181-4231</orcidid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0171-5216 |
| ispartof | Journal of cancer research and clinical oncology, 2022-04, Vol.148 (4), p.975-984 |
| issn | 0171-5216 1432-1335 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2543444297 |
| source | SpringerLink Journals |
| subjects | Antineoplastic drugs Antiplatelet therapy Antitumor agents Cancer Research Drugs Hematology Immunomodulation Immunomodulators Internal Medicine Life Sciences Medicine Medicine & Public Health Multiple myeloma Oncology Original Article – Clinical Oncology Patients Thalidomide Thromboembolism Thrombosis |
| title | Thromboembolic events and thromboprophylaxis associated with immunomodulators in multiple myeloma patients: a real-life study |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-09T04%3A12%3A11IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_hal_p&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Thromboembolic%20events%20and%20thromboprophylaxis%20associated%20with%20immunomodulators%20in%20multiple%20myeloma%20patients:%20a%20real-life%20study&rft.jtitle=Journal%20of%20cancer%20research%20and%20clinical%20oncology&rft.au=Leclerc,%20V.&rft.date=2022-04-01&rft.volume=148&rft.issue=4&rft.spage=975&rft.epage=984&rft.pages=975-984&rft.issn=0171-5216&rft.eissn=1432-1335&rft_id=info:doi/10.1007/s00432-021-03693-5&rft_dat=%3Cproquest_hal_p%3E2640563778%3C/proquest_hal_p%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2640563778&rft_id=info:pmid/34143239&rfr_iscdi=true |